Quest Diagnostics, Inc (NYSE: DGX) has a higher price-to-earnings ratio of 21.05x compared to its average ratio, The 36-month beta value for DGX is at 0.89. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 1 rating it as “overweight,” 14 as “hold,” and 1 as “sell.”
The public float for DGX is 111.06M, and currently, shorts hold a 2.14% of that float. The average trading volume for DGX on November 15, 2024 was 730.98K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DGX) stock’s latest price update
Quest Diagnostics, Inc (NYSE: DGX)’s stock price has decreased by -2.31 compared to its previous closing price of 160.55. However, the company has seen a 0.41% increase in its stock price over the last five trading sessions. zacks.com reported 2024-11-13 that Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
DGX’s Market Performance
DGX’s stock has risen by 0.41% in the past week, with a monthly rise of 5.31% and a quarterly rise of 3.61%. The volatility ratio for the week is 2.10% while the volatility levels for the last 30 days are 2.04% for Quest Diagnostics, Inc The simple moving average for the last 20 days is 0.51% for DGX stock, with a simple moving average of 10.66% for the last 200 days.
Analysts’ Opinion of DGX
Many brokerage firms have already submitted their reports for DGX stocks, with Robert W. Baird repeating the rating for DGX by listing it as a “Outperform.” The predicted price for DGX in the upcoming period, according to Robert W. Baird is $182 based on the research report published on October 23, 2024 of the current year 2024.
Evercore ISI, on the other hand, stated in their research note that they expect to see DGX reach a price target of $165. The rating they have provided for DGX stocks is “In-line” according to the report published on August 28th, 2024.
Citigroup gave a rating of “Buy” to DGX, setting the target price at $165 in the report published on July 10th of the current year.
DGX Trading at 1.95% from the 50-Day Moving Average
After a stumble in the market that brought DGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.54% of loss for the given period.
Volatility was left at 2.04%, however, over the last 30 days, the volatility rate increased by 2.10%, as shares surge +5.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.69% upper at present.
During the last 5 trading sessions, DGX rose by +0.41%, which changed the moving average for the period of 200-days by +22.12% in comparison to the 20-day moving average, which settled at $156.05. In addition, Quest Diagnostics, Inc saw 13.75% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DGX starting from DEPPE MICHAEL J, who sale 18,755 shares at the price of $154.05 back on Nov 06 ’24. After this action, DEPPE MICHAEL J now owns 34,941 shares of Quest Diagnostics, Inc, valued at $2,889,123 using the latest closing price.
KUPPUSAMY KARTHIK, the SVP, Clinical Solutions of Quest Diagnostics, Inc, sale 1,775 shares at $156.92 during a trade that took place back on Oct 28 ’24, which means that KUPPUSAMY KARTHIK is holding 9,734 shares at $278,525 based on the most recent closing price.
Stock Fundamentals for DGX
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.32 for the gross margin
The net margin for Quest Diagnostics, Inc stands at 0.09. The total capital return value is set at 0.09. Equity return is now at value 12.66, with 5.67 for asset returns.
Based on Quest Diagnostics, Inc (DGX), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at 0.22. The debt to equity ratio resting at 0.92. The interest coverage ratio of the stock is 6.86.
Currently, EBITDA for the company is 1.73 billion with net debt to EBITDA at 3.49. When we switch over and look at the enterprise to sales, we see a ratio of 2.49. The receivables turnover for the company is 6.93for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.
Conclusion
In conclusion, Quest Diagnostics, Inc (DGX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
